Saveetha Dental College introduces dynamic navigation system in India biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally.
New Delhi:
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year that had Patanjali Research Institute s Acharya Balkrishna as the lead author.
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
May 17, 2021
“Saveetha Hospital is managing one of the highest numbers of COVID-19 patients among the private hospitals in the country. The hospital has successfully treated more than 6500 patients so far. The hospital has allocated 500 COVID beds, which includes 250 oxygen beds, 50 COVID ICU beds and 80 HDU beds with occupancy of nearly 100% in the second wave. The hospital has managed more than 900 critically ill patients in the COVID ICU, and is running a successful ECMO program for COVID patients,” said Dr. N.M. Veeraiyan, Founder and Chancellor SIMATS.
The COVID patients are managed by 15 teams of doctors who are ably supported by nursing and physiotherapy professionals who provide high quality care 24×7. COVID ICU is highly equipped with 35 high end ventilators, 10 BIPAPA & CPAP machines, High frequency Nasal Oxygen, ECMO machines, dialysis machines, etc. The COVID treatment is done as per National and state guidelines and protocols.